Trials / Not Yet Recruiting
Not Yet RecruitingNCT05979909
Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
Preventing Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract: a Pilot Randomized Trial of a Single Prophylactic Bladder Instillation of Mitomycin C After Diagnostic Ureteroscopy
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- McMaster University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this pilot study is to determine the feasibility of conducting a phase III randomized trial of intravesical mitomycin C (MMC) for prevention of intravesical recurrence (IVR) after diagnostic ureteroscopy for suspected upper tract urothelial carcinoma (UTUC). In the current study, 40 patients will be randomized to receive MMC or no intervention and will be followed for two years to determine the incidence of adverse events and IVR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitomycin C | Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2025-09-01
- Completion
- 2027-09-01
- First posted
- 2023-08-07
- Last updated
- 2023-08-07
Source: ClinicalTrials.gov record NCT05979909. Inclusion in this directory is not an endorsement.